Close Menu

NEW YORK – Mission Bio said today that it has raised $70 million in a Series C funding round.

The South San Francisco-based firm said it will use the funding to scale its Tapestri singe-cell multi-omics technology, to expand the company's reach in more effective clinical trials for novel cancer treatments, as well as characterization for cell and gene therapy.

Mission Bio's Tapestri platform can simultaneously detect DNA and protein changes from the same cell, which it believes is necessary for developing impactful precision therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.